These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 35373094)

  • 1. Autosomal Dominant Polycystic Kidney Disease Does Not Significantly Alter Major COVID-19 Outcomes among Veterans.
    Cui X; Gallini JW; Jasien CL; Mrug M
    Kidney360; 2021 Jun; 2(6):983-988. PubMed ID: 35373094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autosomal Dominant Polycystic Kidney Disease does not significantly alter major COVID-19 outcomes among veterans.
    Cui X; Gallini JW; Jasien CL; Mrug M
    medRxiv; 2020 Nov; ():. PubMed ID: 33269373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does type 2 diabetes mellitus delay renal failure in autosomal dominant polycystic kidney disease?
    Backenroth R; Popovtzer MM
    Ren Fail; 2002 Nov; 24(6):803-13. PubMed ID: 12472202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autosomal-dominant polycystic kidney disease as a risk factor for diabetes mellitus following renal transplantation.
    de Mattos AM; Olyaei AJ; Prather JC; Golconda MS; Barry JM; Norman DJ
    Kidney Int; 2005 Feb; 67(2):714-20. PubMed ID: 15673321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Do metabolic derangements in end-stage polycystic kidney disease differ versus other primary kidney diseases?
    Jankowska M; Qureshi AR; Barany P; Heimburger O; Stenvinkel P; Lindholm B
    Nephrology (Carlton); 2018 Jan; 23(1):31-36. PubMed ID: 27653449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypomagnesaemia is absent in children with autosomal dominant polycystic kidney disease.
    Seeman T; Fořtová M; Sopko B; Průša R; Pohl M; John U
    Ann Clin Biochem; 2019 Jan; 56(1):90-94. PubMed ID: 29874928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hospital-based inpatient resource utilization associated with autosomal dominant polycystic kidney disease in the US.
    Blanchette CM; Craver C; Belk KW; Lubeck DP; Rossetti S; Gutierrez B
    J Med Econ; 2015 Apr; 18(4):303-11. PubMed ID: 25372357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The association of serum angiogenic growth factors with renal structure and function in patients with adult autosomal dominant polycystic kidney disease.
    Coban M; Inci A
    Int Urol Nephrol; 2018 Jul; 50(7):1293-1300. PubMed ID: 29654395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of intracranial hemorrhage associated with autosomal dominant polycystic kidney disease in patients with end stage renal disease.
    Yoo DJ; Agodoa L; Yuan CM; Abbott KC; Nee R
    BMC Nephrol; 2014 Feb; 15():39. PubMed ID: 24571546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical problems in hemodialysis patients with autosomal dominant polycystic kidney disease.
    Kocyigit I; Eroglu E; Gungor O
    Semin Dial; 2018 May; 31(3):268-277. PubMed ID: 29664556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of ESRD in patients with autosomal dominant polycystic kidney disease.
    Alam A; Perrone RD
    Adv Chronic Kidney Dis; 2010 Mar; 17(2):164-72. PubMed ID: 20219619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. α-lipoic acid in patients with autosomal dominant polycystic kidney disease.
    Lai S; Petramala L; Muscaritoli M; Cianci R; Mazzaferro S; Mitterhofer AP; Pasquali M; D'Ambrosio V; Carta M; Ansuini M; Ramaccini C; Galani A; Amabile MI; Molfino A; Letizia C
    Nutrition; 2020 Mar; 71():110594. PubMed ID: 31790890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Posttransplant Outcomes of Patients With Autosomal Dominant Polycystic Kidney Disease Versus Other Recipients: A 10-Year Report From South of Iran.
    Roozbeh J; Malekmakan L; Harifi MM; Tadayon T
    Exp Clin Transplant; 2018 Dec; 16(6):676-681. PubMed ID: 27759554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers as first-line treatment in autosomal dominant polycystic kidney disease.
    Clark LA; Whitmire S; Patton S; Clark C; Blanchette CM; Howden R
    J Med Econ; 2017 Jul; 20(7):715-722. PubMed ID: 28332417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Co-Inheritance of Autosomal Dominant Polycystic Kidney Disease and Naevoid Basal Cell Carcinoma Syndrome: Effects on Renal Progression.
    Martínez MF; Mazzuoccolo LD; Oddo EM; Iscoff PV; Muchnik C; Neumann HPH; Martin RS; Fraga AR; Azurmendi PJ
    Nephron; 2018; 140(4):282-288. PubMed ID: 30368514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ESRD from autosomal dominant polycystic kidney disease in the United States, 2001-2010.
    Reule S; Sexton DJ; Solid CA; Chen SC; Collins AJ; Foley RN
    Am J Kidney Dis; 2014 Oct; 64(4):592-9. PubMed ID: 25134777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between anemia and renal prognosis in autosomal dominant polycystic kidney disease: a retrospective study.
    Ushio Y; Kataoka H; Sato M; Manabe S; Watanabe S; Akihisa T; Makabe S; Yoshida R; Tsuchiya K; Nitta K; Mochizuki T
    Clin Exp Nephrol; 2020 Jun; 24(6):500-508. PubMed ID: 32036465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peritoneal Dialysis for Patients with Autosomal Dominant Polycystic Kidney Disease.
    Khan S; Giuliani A; Crepaldi C; Ronco C; Rosner MH
    Perit Dial Int; 2017; 37(4):384-388. PubMed ID: 28676509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Excess healthcare costs in patients with autosomal dominant polycystic kidney disease by renal dysfunction stage.
    Gagnon-Sanschagrin P; Liang Y; Sanon M; Oberdhan D; Guérin A; Cloutier M
    J Med Econ; 2021; 24(1):193-201. PubMed ID: 33464936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RAPID-ADPKD (Retrospective epidemiological study of Asia-Pacific patients with rapId Disease progression of Autosomal Dominant Polycystic Kidney Disease): study protocol for a multinational, retrospective cohort study.
    Ryu H; Park HC; Oh YK; Sangadi I; Wong A; Mei C; Ecder T; Wang AY; Kao TW; Huang JW; Rangan GK; Ahn C
    BMJ Open; 2020 Feb; 10(2):e034103. PubMed ID: 32034027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.